[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2093905T3 - Nuevo procedimiento para la obtencion de derivados de la n4-acil-5'-desoxi-5-fluorocitidina. - Google Patents

Nuevo procedimiento para la obtencion de derivados de la n4-acil-5'-desoxi-5-fluorocitidina.

Info

Publication number
ES2093905T3
ES2093905T3 ES93119528T ES93119528T ES2093905T3 ES 2093905 T3 ES2093905 T3 ES 2093905T3 ES 93119528 T ES93119528 T ES 93119528T ES 93119528 T ES93119528 T ES 93119528T ES 2093905 T3 ES2093905 T3 ES 2093905T3
Authority
ES
Spain
Prior art keywords
deoxy
acyl
derivatives
fluorocitidine
desoxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93119528T
Other languages
English (en)
Inventor
Takashi Kamiya
Makoto Ishiduka
Hiroshi Nakajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Fuji Chemical Industries Co Ltd
Original Assignee
F Hoffmann La Roche AG
Fuji Chemical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Fuji Chemical Industries Co Ltd filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2093905T3 publication Critical patent/ES2093905T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE PRESENTA UN NUEVO PROCESO PARA PRODUCIR DERIVADOS DEL N4-ACIL5''-DEOXI-5-FLUOROCITIDINA USANDO LOS NUEVOS DERIVADOS DE LA 5''-DEOXI5-FLUORO-N4-2''-O,3''-O-TRIACILCITIDINA. SE HACE REACCIONAR 5-DEOXI1,2,3-TRI-O-ACIL-(BETA)-D-RIBOFURANOSURO CON 5-FLUOROCITOSINA PARA PRODUCIR 5''-DEOXI-2''-3''-DI-O-ACIL-5-FLUOROCITIDINA, REALIZANDOSE POSTERIORMENTE SU ACILACION. LOS RADICALES DE ACILO DE LA 5-DEOXI-5FLUORO-N4-2''-O,3''-O-TRIACILCITIDINA OBTENIDA SON SELECTIVAMENTE DESO-ACILADOS PARA OBTENER DERIVADOS DE LA N4-ACIL-5''-DEOXI-5FLUOROCITIDINA. A PARTIR DE LA FLUOROCITOSINA PUEDEN OBTENERSE DERIVADOS DE LA N4-ACIL-5''-DEOXI-5-FLUOROCITIDINA A TRAVES DE MUY POCOS PASOS Y CON UN MUY ALTO RENDIMIENTO.
ES93119528T 1992-12-18 1993-12-03 Nuevo procedimiento para la obtencion de derivados de la n4-acil-5'-desoxi-5-fluorocitidina. Expired - Lifetime ES2093905T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121539 1992-12-18

Publications (1)

Publication Number Publication Date
ES2093905T3 true ES2093905T3 (es) 1997-01-01

Family

ID=8210305

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93119528T Expired - Lifetime ES2093905T3 (es) 1992-12-18 1993-12-03 Nuevo procedimiento para la obtencion de derivados de la n4-acil-5'-desoxi-5-fluorocitidina.

Country Status (13)

Country Link
US (1) US5453497A (es)
EP (1) EP0602478B1 (es)
JP (2) JP3530218B2 (es)
KR (1) KR100343481B1 (es)
CN (1) CN1035675C (es)
AT (1) ATE140923T1 (es)
CA (1) CA2110335C (es)
CY (1) CY2154B1 (es)
DE (1) DE69303879T2 (es)
DK (1) DK0602478T3 (es)
ES (1) ES2093905T3 (es)
RU (1) RU2131879C1 (es)
TW (1) TW254946B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
US7105527B2 (en) * 2001-12-14 2006-09-12 Otto Michael J N4-acylcytosine nucleosides for treatment of viral infections
EP1589027A1 (en) * 2003-01-17 2005-10-26 Ajinomoto Co., Inc. Processes for production of nucleosides
CA2550299C (en) * 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
US20050192433A1 (en) * 2004-02-26 2005-09-01 Mitsui Chemicals, Inc. Metallic salt of N4-acylcytidine derivatives, and a method for producing N4-acylcytidine derivatives using the same
JP4627625B2 (ja) * 2004-03-11 2011-02-09 三井化学株式会社 Ｎ−アセチルシチジン類の製造方法
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
RU2405566C2 (ru) 2005-02-03 2010-12-10 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
KR20100015568A (ko) * 2007-04-20 2010-02-12 닥터 레디스 레보러터리즈 리미티드 카페시타빈의 제조 방법
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) * 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
EP2225566A1 (en) * 2008-01-03 2010-09-08 Plus Chemicals S.A. Process for the preparation of capecitabine
EP2562163A1 (en) 2008-01-22 2013-02-27 Dow AgroSciences LLC 5-fluoro pyrimidine derivatives as fungicides
EP2656844B1 (en) 2008-06-17 2014-12-03 Wyeth LLC Antineoplastic combinations containing HKI-272 and vinorelbine
EP2326329B1 (en) 2008-08-04 2017-01-11 Wyeth LLC Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010061402A2 (en) * 2008-11-25 2010-06-03 Vishwanath Kannan An improved process for the preparation of capecitabine
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
CN101525362B (zh) * 2009-01-15 2011-05-11 浙江诚意药业有限公司 5’-脱氧-2’,3’-二乙酰-5-氟胞苷的制备方法
FI3000467T3 (fi) 2009-04-06 2023-03-28 Wyeth Llc Rintasyöpähoitokuuri, jossa käytetään neratinibia
EP2456778A4 (en) * 2009-07-23 2013-05-29 Scinopharm Taiwan Ltd PROCESS FOR PRODUCING FLUOROCYTIDINE DERIVATIVES
CN102190695B (zh) * 2010-03-18 2013-12-18 齐鲁制药有限公司 5’-脱氧-2’，3’-二乙酰-5-氟胞苷的制备方法
CN101830952A (zh) * 2010-04-22 2010-09-15 上海柯林斯堡医药科技有限公司 2’,3’-o-二乙酰基-5’-脱氧-5-氟胞苷的制备方法
CN101830953A (zh) * 2010-05-26 2010-09-15 南京亚东启天药业有限公司 一种卡培他滨及其中间体的制备方法
WO2013063336A1 (en) * 2011-10-25 2013-05-02 Virginia Tech Intellectual Properties, Inc. Regioselectively substituted cellulose esters and efficient methods of preparing them
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
CN103570781B (zh) * 2012-07-02 2016-01-13 国药一心制药有限公司 一种卡培他滨的工业化制备方法
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
MX384144B (es) * 2016-06-28 2025-03-14 Cellix Bio Private Ltd Composiciones y métodos para el tratamiento del cáncer.
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
US20210171564A1 (en) * 2018-08-03 2021-06-10 Cellix Bio Provate Limited Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
CN111100172B (zh) * 2019-12-11 2023-03-17 中国科学院昆明植物研究所 一种胞嘧啶核苷衍生物及该衍生物制备卡培他滨药物的方法
WO2022049462A1 (en) * 2020-09-05 2022-03-10 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
EP0373485B1 (en) * 1988-12-07 1995-05-31 Yamasa Shoyu Co., Ltd. Pyrimidine 2'-methylidene nucleoside compounds
JPH0576898A (ja) * 1991-09-20 1993-03-30 Hitachi Kiden Kogyo Ltd スクリーン渣の破砕洗浄装置
FR2684997A1 (fr) 1991-12-12 1993-06-18 Centre Nat Rech Scient Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
CA2110335A1 (en) 1994-06-19
JP3530218B2 (ja) 2004-05-24
ATE140923T1 (de) 1996-08-15
CN1095070A (zh) 1994-11-16
KR940014429A (ko) 1994-07-18
DE69303879D1 (de) 1996-09-05
TW254946B (es) 1995-08-21
RU2131879C1 (ru) 1999-06-20
JP2004123758A (ja) 2004-04-22
EP0602478A1 (en) 1994-06-22
KR100343481B1 (ko) 2002-11-23
US5453497A (en) 1995-09-26
DE69303879T2 (de) 1997-01-30
JPH07300492A (ja) 1995-11-14
CA2110335C (en) 2004-01-20
EP0602478B1 (en) 1996-07-31
DK0602478T3 (da) 1996-09-30
CN1035675C (zh) 1997-08-20
CY2154B1 (en) 2002-08-23
JP4202274B2 (ja) 2008-12-24

Similar Documents

Publication Publication Date Title
ES2093905T3 (es) Nuevo procedimiento para la obtencion de derivados de la n4-acil-5'-desoxi-5-fluorocitidina.
RU93055875A (ru) Новый способ получения производных n*994-ацил-5'-дезокси-5-флюороцитидина
MX9202395A (es) Procesos para la sintesis diastereoselectiva de nucleosidos.
FI101793B1 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonihappojohdannaisten valmistamiseksi
DK0670845T3 (da) Fremgangsmåde til fremstilling af fludarabinphosphat ud fra guanosin
HUT41795A (en) Process for producing pyrimidine derivatives
ATE162530T1 (de) 5-methyluridin-verfahren zur herstellung von 2',3'-didehydro-3'-desoxythymidin (d4t) im grossmassstab
EP0021231A3 (en) Process for the preparation of 5'-deoxy-5-fluoro uridine and intermediates in this process as well as their application
FI945322A0 (fi) Menetelmä 2',3'-didehydro-2',3'-dideoksinukleosidien laajamittaista valmistusta varten
HUT61601A (en) Process for producing rebeccamycin analogs
NO974512D0 (no) Fremgangsmåte for syntese av nukleosid-analoger
EP0311694A4 (en) Nucleoside derivatives and process for their preparation
BG105624A (en) Process for preparing n6-substituted deaza-adenosine derivatives
TH9308A (th) พิริมิดีนคลีโอไซด์ที่ใช้ต้านไวรัส
IL102144A0 (en) Process for producing 2'-deoxy-2',2'-difluoro nucleosides
GB1521644A (en) Agent for inhibiting cell growth
FI960286L (fi) Välituotteita nukleosidien diastereoselektiivisiin synteesimenetelmiin

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 602478

Country of ref document: ES